IGC Pharma Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence

Reuters

2025/05/22

<a href="https://laohu8.com/S/IGC">IGC Pharma</a> Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence

IGC Pharma Inc. has announced the initiation of a clinical trial site at Santa Cruz Behavioral in Puerto Rico as part of its CALMA Phase 2 clinical trial. The study is focused on evaluating IGC-AD1, a cannabinoid-based therapy, for managing agitation in Alzheimer's disease patients. This initiative addresses the higher prevalence of Alzheimer's among Puerto Ricans over age 65, which stands at approximately 12.5%. The trial aims to explore the safety and efficacy of IGC-AD1, which functions as a partial CB1 receptor agonist with anti-neuroinflammatory properties. The inclusion of diverse populations in the trial is expected to enhance the scientific validity and commercial viability of the therapy. Interested patients and caregivers are encouraged to contact Santa Cruz Behavioral in Bayamon for participation details.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1030732) on May 22, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537941072"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537941072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537941072?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537941072","market":"nz","top_or_hot":-1,"title":"IGC Pharma Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IGC\">IGC Pharma</a> Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IGC Pharma Inc. has announced the initiation of a clinical trial site at Santa Cruz Behavioral in Puerto Rico as part of its CALMA Phase 2 clinical trial. The study is focused on evaluating IGC-AD1, a cannabinoid-based therapy, for managing agitation in Alzheimer's disease patients. This initiative addresses the higher prevalence of Alzheimer's among Puerto Ricans over age 65, which stands at approximately 12.5%. The trial aims to explore the safety and efficacy of IGC-AD1, which functions as a partial CB1 receptor agonist with anti-neuroinflammatory properties. The inclusion of diverse populations in the trial is expected to enhance the scientific validity and commercial viability of the therapy. Interested patients and caregivers are encouraged to contact Santa Cruz Behavioral in Bayamon for participation details.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1030732) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IGC Pharma Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIGC Pharma Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-22 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IGC\">IGC Pharma</a> Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IGC Pharma Inc. has announced the initiation of a clinical trial site at Santa Cruz Behavioral in Puerto Rico as part of its CALMA Phase 2 clinical trial. The study is focused on evaluating IGC-AD1, a cannabinoid-based therapy, for managing agitation in Alzheimer's disease patients. This initiative addresses the higher prevalence of Alzheimer's among Puerto Ricans over age 65, which stands at approximately 12.5%. The trial aims to explore the safety and efficacy of IGC-AD1, which functions as a partial CB1 receptor agonist with anti-neuroinflammatory properties. The inclusion of diverse populations in the trial is expected to enhance the scientific validity and commercial viability of the therapy. Interested patients and caregivers are encouraged to contact Santa Cruz Behavioral in Bayamon for participation details.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1030732) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IGC","symbol_name":"IGC Pharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLqKnyM:1","article_id":"2537941072","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537941072","pubTimestamp":1747920626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IGC Pharma Inc. has announced the initiation of a clinical trial site at Santa Cruz Behavioral in Puerto Rico as part of its CALMA Phase 2 clinical trial. The study is focused on evaluating IGC-AD1, a cannabinoid-based therapy, for managing agitation in Alzheimer's disease patients. This initiative addresses the higher prevalence of Alzheimer's among Puerto Ricans over age 65, which stands at approximately 12.5%. The trial aims to explore the safety and efficacy of IGC-AD1, which functions as a partial CB1 receptor agonist with anti-neuroinflammatory properties. The inclusion of diverse populations in the trial is expected to enhance the scientific validity and commercial viability of the therapy. Interested patients and caregivers are encouraged to contact Santa Cruz Behavioral in Bayamon for participation details.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IGC":"IGC Pharma","BK4007":"制药","BK4104":"贸易公司与经销商"},"translate_title":"IGC Pharma Inc.在波多黎各启动新的CALMA 2期临床试验点，以解决阿尔茨海默病的高患病率问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IGC":0.9},"content_text":"IGC Pharma Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence\n    \n\n        IGC Pharma Inc. has announced the initiation of a clinical trial site at Santa Cruz Behavioral in Puerto Rico as part of its CALMA Phase 2 clinical trial. The study is focused on evaluating IGC-AD1, a cannabinoid-based therapy, for managing agitation in Alzheimer's disease patients. This initiative addresses the higher prevalence of Alzheimer's among Puerto Ricans over age 65, which stands at approximately 12.5%. The trial aims to explore the safety and efficacy of IGC-AD1, which functions as a partial CB1 receptor agonist with anti-neuroinflammatory properties. The inclusion of diverse populations in the trial is expected to enhance the scientific validity and commercial viability of the therapy. Interested patients and caregivers are encouraged to contact Santa Cruz Behavioral in Bayamon for participation details.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1030732) on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}